Costs and outcomes associated with IVF using recombinant FSH.
Cost and outcome estimates based on clinical trial data may not reflect usual clinical practice, yet they are often used to inform service provision and budget decisions. To expand understanding of assisted reproduction treatment in clinical practice, an economic evaluation of IVF/intracytoplasmic sperm injection (ICSI) data from a single assisted conception unit (ACU) in England was performed. A total of 1418 IVF/ICSI cycles undertaken there between October 2001 and January 2006 in 1001 women were analysed. The overall live birth rate was 22% (95% CI: 19.7-24.2), with the 30- to 34-year age group achieving the highest rate (28%). The average recombinant FSH (rFSH) dose/cycle prescribed was 1855 IU. Average cost of rFSH/cycle was 646 pound(SD: 219 pound), and average total cost/cycle was 2932 pound (SD: 422 pound). Economic data based on clinical trials informing current UK guidance assumes higher doses of rFSH dose/cycle (1750-2625 IU), higher average cost of drugs/cycle (1179 pound), and higher average total cost/cycle (3266 pound). While the outcomes in this study matched UK averages, total cost/cycle was lower than those cited in UK guidelines. Utilizing the protocols and (lower) rFSH dosages reported in this study may enable other ACU to provide a greater number of IVF/ICSI cycles to patients within given budgets.
Ledger
W
W
Centre for Reproductive Medicine and Fertility, Royal Hallamshire Hospital, Sheffield, UK.
Wiebinga
C
C
Anderson
P
P
Irwin
D
D
Holman
A
A
Lloyd
A
A
D000328:Adult; D003365:Costs and Cost Analysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000191:economics; D005307:Fertilization in Vitro / Q000191:economics* / Q000379:methods; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000191:economics*; D019983:Guideline Adherence; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000191:economics*; D008423:Maternal Age; D011247:Pregnancy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000191:economics; D020554:Sperm Injections, Intracytoplasmic / Q000191:economics; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone